BioNTech SE
BioNTech SE (BNTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BNTX · as of Jun 8, 2026
Key Statistics
Explore BioNTech SE Data
bntx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 24 · Buy rate: 87.5%
The BNTX analyst consensus is Buy, based on ratings from 24 Wall Street analysts over the past 3 months. The average 12-month price target is $135.09, representing +53.37% upside from the current price of $88.08.
Competitors & Peers
bntx competitorsBNTX
BIIB
DXCM
GMAB
INCY
NTRAStock Performance
Full HistoryAbout BioNTech SE
BioNTech SE a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which…
what is biontech se · bntx stock overview · biontech se company profile · who is biontech se ceo · bntx NASDAQ · biontech se headquarters · biontech se business segments
About Stock Overview & Key Data
BioNTech SE (BNTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 10, 2019. As of the latest trading session, BNTX stock price is $88.08, with a market capitalization of $22.3B. The stock has returned -19.17% over the past 12 months and -7.48% year-to-date.
According to 24 Wall Street analysts, the consensus rating for BioNTech SE stock is Buy, with an average 12-month price target of $135.09. In fiscal year 2025, BioNTech SE reported revenue of $2.8B and net income of -$1.1B. For detailed data — including BioNTech SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BioNTech SE (BNTX) stock price is $88.08. The stock is traded on NASDAQ under the ticker symbol BNTX. The 52-week range is $79.52 – $124.00.